Hironobu Endo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hironobu Endo has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
Kenji Tagai
Advanced Neuroimaging Center, Institute for Quantum Medial Science National Institutes for Quantum Science and Technology (QST) Chiba Japan
11 shared publicationsHitoshi Shinotoh
Advanced Neuroimaging Center, Institute for Quantum Medial Science National Institutes for Quantum Science and Technology (QST) Chiba Japan
9 shared publicationsMakoto Higuchi
Advanced Neuroimaging Center, Institute for Quantum Medial Science National Institutes for Quantum Science and Technology (QST) Chiba Japan
9 shared publications- Keisuke Takahata
Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan
8 shared publications Kosei Hirata
Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan
8 shared publications- Makoto Higuchi
Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan
8 shared publications
Latest Publications
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11)
In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients With Progressive Supranuclear Palsy
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11)
In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients With Progressive Supranuclear Palsy
- Open Access
- 30 October 2026
- Published by MDPI AG in Preprints.org
From Lesion Network Mapping in Humans to Causal Circuit Validation in Animals for Defining Neuromodulation Targets: A Narrative Review
Neuromodulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), have demonstrated efficacy across several neuropsychiatric disorders, yet identifying symptom-specific and biologically informed stimulation targets remains a major challenge. Lesion network mapping (LNM) addresses this problem by treating focal brain lesions as natural perturbations and mapping anatomically heterogeneous lesion locations onto normative connectomes to identify convergent symptom-relevant circuits. Since its introduction in 2015, LNM has generated candidate neuromodulation targets across diverse neurological and psychiatric conditions, with several studies showing overlap between lesion-derived networks, independent neuroimaging findings, and therapeutic neuromodulation targets. However, these observations do not establish whether the identified networks connected to lesion sites are causally responsible for symptom expression or how they should be therapeutically modulated. Because LNM relies on correlation-based connectivity measures, it cannot determine which circuit components or pathways causally mediate the relevant symptom, or whether candidate neuromodulation targets should be activated or inhibited. We therefore propose a translational framework in which LNM-derived circuit hypotheses are examined through cross-species anatomical and functional mapping, region-, cell-, and projection-specific perturbation in animal models, and concurrent behavioral and whole-brain functional readouts, before clinical evaluation. This framework positions LNM as a tool for identifying candidate circuits that are first tested in animal models for causal relevance and perturbation direction, and then evaluated clinically for therapeutic relevance.
- 30 October 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Lesion Network Mapping in Humans to Causal Circuit Validation in Animals for Defining Neuromodulation Targets: A Narrative Review
Neuromodulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), have demonstrated efficacy across several neuropsychiatric disorders, yet identifying symptom-specific and biologically informed stimulation targets remains a major challenge. Lesion network mapping (LNM) addresses this problem by treating focal brain lesions as natural perturbations and mapping anatomically heterogeneous lesion locations onto normative connectomes to identify convergent symptom-relevant circuits. Since its introduction in 2015, LNM has generated candidate neuromodulation targets across diverse neurological and psychiatric conditions, with several studies showing overlap between lesion-derived networks, independent neuroimaging findings, and therapeutic neuromodulation targets. However, these observations do not establish whether the identified networks connected to lesion sites are causally responsible for symptom expression or how they should be therapeutically modulated. Because LNM relies on correlation-based connectivity measures, it cannot determine which circuit components or pathways causally mediate the relevant symptom, or whether candidate neuromodulation targets should be activated or inhibited. We therefore propose a translational framework in which LNM-derived circuit hypotheses are examined through cross-species anatomical and functional mapping, region-, cell-, and projection-specific perturbation in animal models, and concurrent behavioral and whole-brain functional readouts, before clinical evaluation. This framework positions LNM as a tool for identifying candidate circuits that are first tested in animal models for causal relevance and perturbation direction, and then evaluated clinically for therapeutic relevance.
- Open Access
- 9 September 2026
- Published by Springer Nature in BMC Medical Imaging
TAME-Q: an open-source preprocessing pipeline for reproducible semi-quantification of florzolotau (18 F) PET
Background: Florzolotau (18 F) PET can visualise tau aggregates in Alzheimer’s disease (AD) and non-AD tauopathies. A previously developed histogram-based grey-matter reference strategy enables semi-quantification without prespecifying a single anatomically spared reference region, but its reliance on in-house and proprietary tools has limited reproducibility. We developed TAME-Q, an automated, openly accessible pipeline implementing this strategy, and evaluated its technical performance and concordance with the previous workflow. Methods: TAME-Q was applied to dynamic florzolotau PET and T1-weighted MRI from 37 participants on the AD continuum, 46 with progressive supranuclear palsy–Richardson syndrome (PSP-RS), and 50 healthy controls. The pipeline performs image alignment, tissue segmentation, Gaussian fitting of grey-matter intensity histograms, reference estimation, SUVR generation, FreeSurfer-based parcellation, extraction of 132 ROI-level SUVRs, and generation of quality-assurance outputs. Outputs were evaluated using quantitative screening and structured visual review. Disease-specific regional SUVRs and Elastic Net-derived AD-tau and PSP-tau scores were compared with a benchmark implementation. Held-out discrimination across ten 75%/25% shuffle-split iterations and post hoc reduced-feature and atlas-sensitivity analyses were also evaluated. Results: TAME-Q completed automated preprocessing for all 133 participants, and all outputs were accepted after quality control. Bimodal and monomodal histogram fits were used in 121 and 12 participants, respectively. Age- and sex-adjusted SUVRs were higher in the inferior temporal gyrus in AD and in the globus pallidus in PSP-RS (Holm-adjusted p < 0.001). Histogram- and cerebellar-derived reference values showed broadly similar group-level scaling but differed in some individuals. TAME-Q-derived and benchmark tau scores were strongly correlated (AD-tau, r = 0.979; PSP-tau, r = 0.960). Full-cohort AUCs were 0.999 (95% CI: 0.998–1.000) for AD and 0.967 (95% CI: 0.941–0.992) for PSP; corresponding mean held-out AUCs were 0.996 ± 0.009 and 0.935 ± 0.010. Full-cohort AUCs were similar after coefficient truncation to the top 20 ROIs and after retraining with the unmerged FreeSurfer atlas. Conclusions: TAME-Q provides an automated and inspectable implementation of histogram-based florzolotau PET semi-quantification and produced outputs concordant with the benchmark workflow in this single-center dataset. External multicenter validation is required to establish generalisability across acquisition settings and populations.
- 9 September 2026
- Published by Springer Nature in BMC Medical Imaging
Open AccessTAME-Q: an open-source preprocessing pipeline for reproducible semi-quantification of florzolotau (18 F) PET
Background: Florzolotau (18 F) PET can visualise tau aggregates in Alzheimer’s disease (AD) and non-AD tauopathies. A previously developed histogram-based grey-matter reference strategy enables semi-quantification without prespecifying a single anatomically spared reference region, but its reliance on in-house and proprietary tools has limited reproducibility. We developed TAME-Q, an automated, openly accessible pipeline implementing this strategy, and evaluated its technical performance and concordance with the previous workflow. Methods: TAME-Q was applied to dynamic florzolotau PET and T1-weighted MRI from 37 participants on the AD continuum, 46 with progressive supranuclear palsy–Richardson syndrome (PSP-RS), and 50 healthy controls. The pipeline performs image alignment, tissue segmentation, Gaussian fitting of grey-matter intensity histograms, reference estimation, SUVR generation, FreeSurfer-based parcellation, extraction of 132 ROI-level SUVRs, and generation of quality-assurance outputs. Outputs were evaluated using quantitative screening and structured visual review. Disease-specific regional SUVRs and Elastic Net-derived AD-tau and PSP-tau scores were compared with a benchmark implementation. Held-out discrimination across ten 75%/25% shuffle-split iterations and post hoc reduced-feature and atlas-sensitivity analyses were also evaluated. Results: TAME-Q completed automated preprocessing for all 133 participants, and all outputs were accepted after quality control. Bimodal and monomodal histogram fits were used in 121 and 12 participants, respectively. Age- and sex-adjusted SUVRs were higher in the inferior temporal gyrus in AD and in the globus pallidus in PSP-RS (Holm-adjusted p < 0.001). Histogram- and cerebellar-derived reference values showed broadly similar group-level scaling but differed in some individuals. TAME-Q-derived and benchmark tau scores were strongly correlated (AD-tau, r = 0.979; PSP-tau, r = 0.960). Full-cohort AUCs were 0.999 (95% CI: 0.998–1.000) for AD and 0.967 (95% CI: 0.941–0.992) for PSP; corresponding mean held-out AUCs were 0.996 ± 0.009 and 0.935 ± 0.010. Full-cohort AUCs were similar after coefficient truncation to the top 20 ROIs and after retraining with the unmerged FreeSurfer atlas. Conclusions: TAME-Q provides an automated and inspectable implementation of histogram-based florzolotau PET semi-quantification and produced outputs concordant with the benchmark workflow in this single-center dataset. External multicenter validation is required to establish generalisability across acquisition settings and populations.
- Open Access
- 4 September 2026
- Published by Wiley in Movement Disorders
Spatiotemporal Tau Accumulation and its Clinical Impact on Progressive Supranuclear Palsy: Longitudinal Florzolotau ( 18F ) Positron Emission T omography
Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high‐contrast in vivo detection of four‐repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: Twenty‐six patients with PSP (18 Richardson's syndrome [PSP‐RS], 8 non‐RS) and 10 age‐ and sex‐matched healthy controls (HCs) underwent florzolotau PET, magnetic resonance imaging, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVRs) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellar white matter, and minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP‐RS and a univariate correlation (Spearman's ρ = 0.688, P = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to increase with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau‐targeted therapeutic trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 4 September 2026
- Published by Wiley in Movement Disorders
Open AccessSpatiotemporal Tau Accumulation and its Clinical Impact on Progressive Supranuclear Palsy: Longitudinal Florzolotau ( 18F ) Positron Emission T omography
Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high‐contrast in vivo detection of four‐repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: Twenty‐six patients with PSP (18 Richardson's syndrome [PSP‐RS], 8 non‐RS) and 10 age‐ and sex‐matched healthy controls (HCs) underwent florzolotau PET, magnetic resonance imaging, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVRs) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellar white matter, and minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP‐RS and a univariate correlation (Spearman's ρ = 0.688, P = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to increase with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau‐targeted therapeutic trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eaed0348
Remote network for cognitive symptoms derived from tau accumulation in progressive supranuclear palsy
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with motor and cognitive impairments. Whereas motor symptoms are associated with subcortical tau deposits, the mechanisms underlying the cognitive symptoms remain unclear due to heterogeneous and primarily subcortical distribution of pathological tau deposits. Here, we combined tau-PET (tau positron emission tomography) using a high-contrast probe we developed with a normative connectome in 37 patients with PSP and 48 healthy controls. We found that tau deposition sites functionally connected to a common cortical network that could not be derived from atrophy. This network predominantly overlapped with canonical action-mode and frontoparietal networks, which support adaptive, goal-directed behavior. Whereas the extent of primary tau deposition predicted motor symptoms, the normative connectivity strength from tau deposition sites to the identified cortical network explained the severity of cognitive deficits. These findings suggest a previously unknown mechanism that cognitive, but not motor, deficits in PSP arise from remote effects of tau deposition—independent of atrophy—via convergent connectivity to a common cortical network.
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eaed0348
Open AccessRemote network for cognitive symptoms derived from tau accumulation in progressive supranuclear palsy
Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with motor and cognitive impairments. Whereas motor symptoms are associated with subcortical tau deposits, the mechanisms underlying the cognitive symptoms remain unclear due to heterogeneous and primarily subcortical distribution of pathological tau deposits. Here, we combined tau-PET (tau positron emission tomography) using a high-contrast probe we developed with a normative connectome in 37 patients with PSP and 48 healthy controls. We found that tau deposition sites functionally connected to a common cortical network that could not be derived from atrophy. This network predominantly overlapped with canonical action-mode and frontoparietal networks, which support adaptive, goal-directed behavior. Whereas the extent of primary tau deposition predicted motor symptoms, the normative connectivity strength from tau deposition sites to the identified cortical network explained the severity of cognitive deficits. These findings suggest a previously unknown mechanism that cognitive, but not motor, deficits in PSP arise from remote effects of tau deposition—independent of atrophy—via convergent connectivity to a common cortical network.
- Open Access
Spatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PET
Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high-contrast in vivo detection of four-repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: A total of 26 patients with PSP (18 Richardson’s syndrome [PSP-RS], 8 non-RS) and 10 age- and sex-matched healthy controls (HCs) underwent florzolotau PET, MRI, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVR) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellum, whereas minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP-RS and a univariate correlation (Spearman’s ρ = 0.674, p = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to rise with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau-targeted therapeutic trials.
Open AccessSpatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PET
Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high-contrast in vivo detection of four-repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: A total of 26 patients with PSP (18 Richardson’s syndrome [PSP-RS], 8 non-RS) and 10 age- and sex-matched healthy controls (HCs) underwent florzolotau PET, MRI, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVR) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellum, whereas minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP-RS and a univariate correlation (Spearman’s ρ = 0.674, p = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to rise with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau-targeted therapeutic trials.
- Open Access
- 19 January 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (1) , 110
Neuroimaging and Pathology Biomarkers in Parkinson’s Disease and Parkinsonism
The “Neuroimaging and Pathology Biomarkers in Parkinson’s Disease” course held on 12–13 September 2025 in Milan, Italy, convened an international faculty to review state-of-the-art biomarkers spanning neurotransmitter dysfunction, protein pathology and clinical translation. Here, we synthesize the four themed sessions and highlights convergent messages for diagnosis, stratification and trial design. The first session focused on neuroimaging markers of neurotransmitter dysfunction, highlighting how positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) provided complementary insights into dopaminergic, noradrenergic, cholinergic and serotonergic dysfunction. The second session addressed in vivo imaging of protein pathology, presenting recent advances in PET ligands targeting α-synuclein, progress in four-repeat tau imaging for progressive supranuclear palsy and corticobasal syndromes, and the prognostic relevance of amyloid imaging in the context of mixed pathologies. Imaging of neuroinflammation captures inflammatory processes in vivo and helps study pathophysiological effects. The third session bridged pathology and disease mechanisms, covering the biology of α-synuclein and emerging therapeutic strategies, the clinical potential of seed amplification assays and skin biopsy, the impact of co-pathologies on disease expression, and the “brain-first” versus “body-first” model of pathological spread. Finally, the fourth session addressed disease progression and clinical translation, focusing on imaging predictors of phenoconversion from prodromal to clinically overt stages of synucleinopathies, concepts of neural reserve and compensation, imaging correlates of cognitive impairment, and MRI approaches for atypical parkinsonism. Biomarker-informed pharmacological, infusion-based, and surgical strategies, including network-guided and adaptive deep brain stimulation, were discussed as examples of how multimodal biomarkers may inform personalized management. Across all sessions, the need for harmonization, longitudinal validation, and pathology-confirmed outcome measures was consistently emphasized as essential for advancing biomarker qualification in multicentre research and clinical practice.
- 19 January 2026
- Published by MDPI AG in Brain Sciences
- Vol. 16 (1) , 110
Open AccessNeuroimaging and Pathology Biomarkers in Parkinson’s Disease and Parkinsonism
The “Neuroimaging and Pathology Biomarkers in Parkinson’s Disease” course held on 12–13 September 2025 in Milan, Italy, convened an international faculty to review state-of-the-art biomarkers spanning neurotransmitter dysfunction, protein pathology and clinical translation. Here, we synthesize the four themed sessions and highlights convergent messages for diagnosis, stratification and trial design. The first session focused on neuroimaging markers of neurotransmitter dysfunction, highlighting how positron emission tomography (PET), single photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) provided complementary insights into dopaminergic, noradrenergic, cholinergic and serotonergic dysfunction. The second session addressed in vivo imaging of protein pathology, presenting recent advances in PET ligands targeting α-synuclein, progress in four-repeat tau imaging for progressive supranuclear palsy and corticobasal syndromes, and the prognostic relevance of amyloid imaging in the context of mixed pathologies. Imaging of neuroinflammation captures inflammatory processes in vivo and helps study pathophysiological effects. The third session bridged pathology and disease mechanisms, covering the biology of α-synuclein and emerging therapeutic strategies, the clinical potential of seed amplification assays and skin biopsy, the impact of co-pathologies on disease expression, and the “brain-first” versus “body-first” model of pathological spread. Finally, the fourth session addressed disease progression and clinical translation, focusing on imaging predictors of phenoconversion from prodromal to clinically overt stages of synucleinopathies, concepts of neural reserve and compensation, imaging correlates of cognitive impairment, and MRI approaches for atypical parkinsonism. Biomarker-informed pharmacological, infusion-based, and surgical strategies, including network-guided and adaptive deep brain stimulation, were discussed as examples of how multimodal biomarkers may inform personalized management. Across all sessions, the need for harmonization, longitudinal validation, and pathology-confirmed outcome measures was consistently emphasized as essential for advancing biomarker qualification in multicentre research and clinical practice.
- Open Access
Florzolotau (18F) PET provides in-vivo measures of tau pathology in progressive supranuclear palsy: An imaging-postmortem correlation study
The clinical diagnosis of 4-repeat tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration, remains challenging. Although patients may present with characteristic clinical features suggestive of these diseases, discrepancies frequently arise between antemortem diagnosis and postmortem pathological findings. Reliable biomarkers for in vivo detection of tau deposition are therefore urgently needed. We report a case of a man in his 60s who developed progressive gait disturbance and cerebellar ataxia. Based on clinical findings, PSP with predominant cerebellar ataxia (PSP-C) was suspected, and tau positron emission tomography (PET) using florzolotau (18F) ([ 18 F]florzolotau) was performed. The PET scan revealed marked tracer retention in the upper brainstem, bilateral diencephalon, and basal ganglia, consistent with the PSP-C phenotype. The patient died of aspiration pneumonia three years after the first visit, and a neuropathological examination confirmed PSP, showing neuronal and glial tau aggregates, including tufted astrocytes, primarily in the midbrain, pons, dentate nucleus and subthalamic nucleus. To quantitatively assess the concordance between in vivo and postmortem findings, tau burden was measured across 48 representative brain regions using AT8 immunohistochemistry and a binarization-based quantification method. Regional tau pathology presented a strong positive correlation with the standardized uptake value ratio of [ 18 F]florzolotau derived from the antemortem PET data. In conclusion, this study provides direct evidence that [ 18 F]florzolotau-PET accurately reflects the regional distribution of tau pathology in PSP. Our findings support the clinical utility of [ 18 F]florzolotau as a sensitive probe for diagnosing 4-repeat tauopathies and for therapeutic evaluations targeting these disorders.
Open AccessFlorzolotau (18F) PET provides in-vivo measures of tau pathology in progressive supranuclear palsy: An imaging-postmortem correlation study
The clinical diagnosis of 4-repeat tauopathies, including progressive supranuclear palsy (PSP) and corticobasal degeneration, remains challenging. Although patients may present with characteristic clinical features suggestive of these diseases, discrepancies frequently arise between antemortem diagnosis and postmortem pathological findings. Reliable biomarkers for in vivo detection of tau deposition are therefore urgently needed. We report a case of a man in his 60s who developed progressive gait disturbance and cerebellar ataxia. Based on clinical findings, PSP with predominant cerebellar ataxia (PSP-C) was suspected, and tau positron emission tomography (PET) using florzolotau (18F) ([ 18 F]florzolotau) was performed. The PET scan revealed marked tracer retention in the upper brainstem, bilateral diencephalon, and basal ganglia, consistent with the PSP-C phenotype. The patient died of aspiration pneumonia three years after the first visit, and a neuropathological examination confirmed PSP, showing neuronal and glial tau aggregates, including tufted astrocytes, primarily in the midbrain, pons, dentate nucleus and subthalamic nucleus. To quantitatively assess the concordance between in vivo and postmortem findings, tau burden was measured across 48 representative brain regions using AT8 immunohistochemistry and a binarization-based quantification method. Regional tau pathology presented a strong positive correlation with the standardized uptake value ratio of [ 18 F]florzolotau derived from the antemortem PET data. In conclusion, this study provides direct evidence that [ 18 F]florzolotau-PET accurately reflects the regional distribution of tau pathology in PSP. Our findings support the clinical utility of [ 18 F]florzolotau as a sensitive probe for diagnosing 4-repeat tauopathies and for therapeutic evaluations targeting these disorders.
- 14 September 2025
- Published by Wiley in Psychogeriatrics
- Vol. 25 (5) , e70094
A Case of Late‐Onset Semantic Dementia With Right‐Predominant Temporal Lobe Atrophy due to Primary Tauopathy
Semantic dementia (SD) is a type of dementia characterized by a loss of semantic memory, typically presenting with left‐predominant temporal lobe atrophy and a frontotemporal lobar degeneration with TDP‐43 (FTLD‐TDP) type C pathology. However, atypical variants, such as those with a late‐onset or right‐predominant atrophy, exhibit considerable pathological diversity. We report an 81‐year‐old woman with atypical SD who presented with impaired naming, mild word comprehension deficits, and prosopagnosia. Brain MRI revealed right‐predominant atrophy in the amygdala, hippocampus, and anterior temporal lobes. Cerebrospinal fluid analysis showed a normal Aβ level, suggesting a non‐Alzheimer's disease pathology. Tau PET imaging demonstrated a high signal in the right anterior temporal lobe, consistent with primary tauopathy. The patient's clinical presentation and imaging findings, particularly the atrophy in the amygdala and hippocampus, as well as the preserved communication ability, raised the possibility of argyrophilic grain disease (AGD) as the underlying pathology. This case highlights the importance of molecular imaging in diagnosing atypical SD. It suggests that AGD should be considered a possible underlying pathology for atypical SD cases, particularly those with late onset and right‐sided predominance. A longer follow‐up and eventual autopsy would be necessary to confirm the pathological diagnosis.
- 14 September 2025
- Published by Wiley in Psychogeriatrics
- Vol. 25 (5) , e70094
A Case of Late‐Onset Semantic Dementia With Right‐Predominant Temporal Lobe Atrophy due to Primary Tauopathy
Semantic dementia (SD) is a type of dementia characterized by a loss of semantic memory, typically presenting with left‐predominant temporal lobe atrophy and a frontotemporal lobar degeneration with TDP‐43 (FTLD‐TDP) type C pathology. However, atypical variants, such as those with a late‐onset or right‐predominant atrophy, exhibit considerable pathological diversity. We report an 81‐year‐old woman with atypical SD who presented with impaired naming, mild word comprehension deficits, and prosopagnosia. Brain MRI revealed right‐predominant atrophy in the amygdala, hippocampus, and anterior temporal lobes. Cerebrospinal fluid analysis showed a normal Aβ level, suggesting a non‐Alzheimer's disease pathology. Tau PET imaging demonstrated a high signal in the right anterior temporal lobe, consistent with primary tauopathy. The patient's clinical presentation and imaging findings, particularly the atrophy in the amygdala and hippocampus, as well as the preserved communication ability, raised the possibility of argyrophilic grain disease (AGD) as the underlying pathology. This case highlights the importance of molecular imaging in diagnosing atypical SD. It suggests that AGD should be considered a possible underlying pathology for atypical SD cases, particularly those with late onset and right‐sided predominance. A longer follow‐up and eventual autopsy would be necessary to confirm the pathological diagnosis.
- 11 August 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (9) , 506-522
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Neurodegenerative diseases such as Alzheimer disease (AD), Parkinson disease, frontotemporal lobar degeneration and multiple system atrophy (MSA) are characterized pathologically by deposition of specific proteins in the brain. Five major neurodegenerative disease-associated proteins - amyloid-β (Aβ), tau, α-synuclein, TAR DNA-binding protein 43 (TDP43) and fused in sarcoma (FUS) - are commonly encountered, and the disease specificity and neurotoxicity of the fibrillar protein assemblies are determined by factors such as the protein type, fibril structure, degree of multimerization and post-translational modifications. This article reviews the latest advances in PET technologies aimed at visualizing neurodegenerative proteinopathies, and highlights the importance of these technologies for emerging diagnostic and therapeutic approaches. PET allows Aβ deposition to be visualized throughout the natural history of AD and following anti-Aβ immunotherapies. However, whether this technology can visualize specific Aβ assembly subspecies primarily targeted by the treatment remains inconclusive. Various PET radiotracers can capture AD-type tau deposits, although only a few are known to react with non-AD tau pathologies, and cryo-electron microscopy has revealed the mode of binding of these compounds to different tau protofibrils. High-contrast PET imaging of α-synuclein lesions in MSA is a recent development in the field, and gradual progress is being made towards visualization of other, less abundant α-synuclein pathologies. Imaging of TDP43 and FUS deposits presents particular challenges, which might be overcome by establishing public-private partnerships focused on biomarker development.
- 11 August 2025
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 21 (9) , 506-522
Advances in PET imaging of protein aggregates associated with neurodegenerative disease
Neurodegenerative diseases such as Alzheimer disease (AD), Parkinson disease, frontotemporal lobar degeneration and multiple system atrophy (MSA) are characterized pathologically by deposition of specific proteins in the brain. Five major neurodegenerative disease-associated proteins - amyloid-β (Aβ), tau, α-synuclein, TAR DNA-binding protein 43 (TDP43) and fused in sarcoma (FUS) - are commonly encountered, and the disease specificity and neurotoxicity of the fibrillar protein assemblies are determined by factors such as the protein type, fibril structure, degree of multimerization and post-translational modifications. This article reviews the latest advances in PET technologies aimed at visualizing neurodegenerative proteinopathies, and highlights the importance of these technologies for emerging diagnostic and therapeutic approaches. PET allows Aβ deposition to be visualized throughout the natural history of AD and following anti-Aβ immunotherapies. However, whether this technology can visualize specific Aβ assembly subspecies primarily targeted by the treatment remains inconclusive. Various PET radiotracers can capture AD-type tau deposits, although only a few are known to react with non-AD tau pathologies, and cryo-electron microscopy has revealed the mode of binding of these compounds to different tau protofibrils. High-contrast PET imaging of α-synuclein lesions in MSA is a recent development in the field, and gradual progress is being made towards visualization of other, less abundant α-synuclein pathologies. Imaging of TDP43 and FUS deposits presents particular challenges, which might be overcome by establishing public-private partnerships focused on biomarker development.